Cas 25812-30-0 Gemfibrozil Hyperlipidemia Drugs Cardiovascular Medications

Basic Information
Place of Origin: China
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Your demand
Delivery Time: Negotiation
Payment Terms: D/P, D/A, L/C, T/T
Supply Ability: Negotiation
Cas No: 25812-30-0 Ec No: 247-280-2
Name: Gemfibrozil Synonyms: 2,2-Dimethyl-5-(2,5-xylyloxy)valeric Acid
Molecular Formula: C15H22O3 Molecular Weight: 250.33
Melting Point: 61-63°C Boiling Point: 158-159°C
Solubility: Practically Insoluble In Water, Very Soluble In Methylene Chloride, Freely Soluble In Anhydrous Ethanol And In Methanol. Density: 1.1109 G/cm3
Risk Codes: R22-63-62-46-36/38-21 Safety Description: S36-53-36/37-26-25
High Light:

CAS No 25812-30-0


25812-30-0 Gemfibrozil


hyperlipidemia medications


Gemfibrozil Cas No 25812-30-0 API; cardiovascular and cerebrovascular; hyperlipidemia




Name Gemfibrozil
Synonyms 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
Molecular Formula C15H22O3
Molecular Weight 250.33
CAS Registry Number 25812-30-0
EINECS Number 247-280-2
Melting point 61-63°C
Boiling point 158-159°C
Solubility Practically insoluble in water, very soluble in methylene chloride, freely soluble in anhydrous ethanol and in methanol.
Density 1.1109 g/cm3
Safety Description S36-53-36/37-26-25
Risk Codes R22-63-62-46-36/38-21


Product Description:

Gemfibrozil is used for hyperlipidemia. It is suitable for patients with severe type IV or V hyperlipoproteinemia, high risk of coronary heart disease and ineffective diet control and weight loss. It is also suitable for patients with type Ⅱ B hyperlipoproteinemia, high risk of coronary heart disease and ineffective diet control, weight loss and other lipid regulating drugs. It can promote the decomposition of peripheral fat, reduce the liver intake of free fatty acids and reduce the formation of triglycerides in the liver, inhibit the synthesis of very low density lipoprotein apolipoprotein, and reduce the formation of very low density lipoprotein. It can decrease triglyceride, increase HDL level and slightly decrease LDL-C.


Product Use:


For hyperlipidemia. It is suitable for patients with severe type ⅳ or ⅴ hyperlipoproteinemia, high risk of coronary heart disease and ineffective treatment of diet control and weight reduction. Also applies to Ⅱ B type high lipoprotein blood disease, coronary heart disease risk and diet control, weight reduction, other lipid regulation drug treatment is ineffective.


Cas  25812-30-0 Gemfibrozil Hyperlipidemia Drugs Cardiovascular Medications 0Cas  25812-30-0 Gemfibrozil Hyperlipidemia Drugs Cardiovascular Medications 1

Product Catalogue:


Number Cas Name
1 41859-67-0 Bezafibrate
2 62571-86-2 Captopril
3 113665-84-2 Clopidogrel
4 75847-73-3 Enalapril
5 49562-28-9 Fenofibrate
6 25812-30-0 Gemfibrozil
7 21187-98-4 Glicalzide
8 138402-11-6 Irbesartan
9 83915-83-7 Lisinopril
10 75330-75-5 Lovastatin
11 79902-63-9 Simvastatin
12 87333-19-5 Ramipril
13 144701-48-4 Telmisartan
14 13649-88-2 Deflazacort
15 50-02-2 Dexamethasone
16 2135-17-3 Flumethasone
17 53-03-2 Prednisone



About us



Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.

In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.

In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.


Contact Details
William Wang

Phone Number : +86-13588430486

WhatsApp : +8613588430486